期刊
THERANOSTICS
卷 8, 期 11, 页码 3038-3058出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.23459
关键词
nanocarriers; endogenous pH-responsive; size change; targeted drug delivery; tumor therapy
资金
- National Natural Science Foundation of China [51603023, 11332003]
- National Key RD Program [2016YFC1102305]
- Fundamental Research Funds for the Central Universities [106112016CDJXY230002, 106112017CDJ ZRPY0012]
- Chongqing Research Program of Basic research and Frontier Technology [cstc2017jcyjAX0186]
- China Postdoctoral Science Foundation [2016M602656, 2017T100682]
- Chongqing Postdoctoral Scientific Research Foundation [Xm2016011]
- Chongqing Engineering Laboratory in Vascular Implants
- Public Experiment Center of State Bioindustrial Base (Chongqing)
Nanotechnology-based antitumor drug delivery systems, known as nanocarriers, have demonstrated their efficacy in recent years. Typically, the size of the nanocarriers is around 100 nm. It is imperative to achieve an optimum size of these nanocarriers which must be designed uniquely for each type of delivery process. For pH-responsive nanocarriers with programmable size, changes in pH (similar to 6.5 for tumor tissue, similar to 5.5 for endosomes, and similar to 5.0 for lysosomes) may serve as an endogenous stimulus improving the safety and therapeutic efficacy of antitumor drugs. This review focuses on current advanced pH-responsive nanocarriers with programmable size changes for anticancer drug delivery. In particular, pH-responsive mechanisms for nanocarrier retention at tumor sites, size reduction for penetrating into tumor parenchyma, escaping from endo/lysosomes, and swelling or disassembly for drug release will be highlighted. Additional trends and challenges of employing these nanocarriers in future clinical applications are also addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据